Viloxazine (Qelbree) for ADHD

Kristen Goodell; Deborah Erlich

KRISTEN GOODELL, MD, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts

DEBORAH ERLICH, MD, MMedEd, Tufts University School of Medicine, Boston, Massachusetts

Am Fam Physician. 2023;107(3):309-310

Author disclosure: No relevant financial relationships.

Viloxazine (Qelbree) is a selective norepinephrine reuptake inhibitor labeled for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children older than six years.¹

Drug	Dosage	Dose form	Cost of full course*
Viloxazine (Qelbree)	Children 6 to 11 years: 100 to 400 mg per day, starting at 100 mg daily and titrating by 100 mg weekly to effective dose	100-mg, 150-mg, 200-mg capsules	$330
	Adults: 200 to 600 mg per day, starting at 200 mg daily and titrating by 200 mg weekly to effective dose	May be swallowed whole or opened and sprinkled on food

DailyMed. Drug label information. Qelbree—viloxazine hydrochloride capsule, extended release. Updated October 10, 2022. Accessed January 30, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aedf408d-0f84-418d-9416-7c39ddb0d29a#S12.3

U.S. National Library of Medicine. Evaluation of SPN-812 (viloxazine extended-release capsule) low dose in children with ADHD. Accessed January 30, 2023. https://www.clinicaltrials.gov/ct2/show/NCT03247530?term=VILOXAZINE&draw=1&rank=3

U.S. National Library of Medicine. Evaluation of SPN-812 (viloxazine extended-release capsule) high dose in children with ADHD. Accessed January 30, 2023. https://www.clinicaltrials.gov/ct2/show/NCT03247543?term=VILOXAZINE&draw=1&rank=4

U.S. National Library of Medicine. Evaluation of SPN-812 (viloxazine extended-release capsule) low dose in adolescents with ADHD. Accessed January 30, 2023. https://www.clinicaltrials.gov/ct2/show/NCT03247517?term=VILOXAZINE&draw=1&rank=6

U.S. National Library of Medicine. Evaluation of SPN-812 (viloxazine extended-release capsule) in adults with ADHD. Accessed January 30, 2023. https://www.clinicaltrials.gov/ct2/show/NCT04016779?term=VILOXAZINE&draw=1&rank=10

Nasser A, Kosheleff AR, Hull JT, et al. Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness scores into clinical global impressions clinical significance levels in four randomized clinical trials of SPN-812 (viloxazine extended-release) in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2021;31(3):214-226.

Storebø OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015(11):CD009885.

Continue Reading

More in AFP

More in PubMed

Subscribe

Issue Access

Continue Reading

More in AFP

More in PubMed